The trial realized each its Principal endpoints, with semaglutide two.4 mg demonstrating statistically major and outstanding advancements in liver fibrosis without any worsening of steatohepatitis, in addition to resolution of steatohepatitis without having worsening of liver fibrosis in individuals with MASH in comparison to placebo.1Other Approac… Read More